What's to watch, when there is excitingIP news to blog about? Just as she was getting settled for some mindless television viewing after a long day, the AmeriKat received news that the USPTO's Patent Trial and Appeal Board (PTAB) has declined to institute two inter partes reviews (IPRs) filed by the Coalition for Affordable Drugs (the brain child of hedge-fund manager Kyle Bass - see AmeriKat post here). The IPRs in respect of US Patent Nos 8,663,685 (see petition here) and 8,007,826 (see petition here) that protect two of the five Orange Book-listed patents for AMPYRA - Acorda's MS drug - attracted considerable attention due to Bass's business model. The theory behind the model was that the Coalition for Affordable Drugs would file IPRs, publicize the challenge (thereby creating information flows in the market) and then bet against the patentee's shares. See Bloomberg and the Wall Street Journal for further details. In both the…
↧